NextPlat NXPL
NASDAQ NXPL
$9.13 -0.30 (-3.18%)
At close: Sep 4, 2026 · 4:00 PM EDT

NextPlat (NXPL) Net Income towards Common Stockholders (2010 - 2026)

NextPlat's (NXPL) quarterly Net Income towards Common Stockholders came in at -$144000.0 in Q2 2026, up 91.95% year-over-year from -$75019.2 in Q2 2025, and up 87.12% quarter-over-quarter from -$1.1 million in Q1 2026.

Analysis

NextPlat (NXPL) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

NextPlat (NXPL) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$144000.0 the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 91.95% year-over-year to -$144000.0 in Q2 2026; TTM through Jun 2026 was -$9.8 million, a 5.05% increase from a year earlier, with the FY2025 full-year figure at -$11.7 million, up 12.77% from the prior year.
  • Net Income towards Common Stockholders was -$144000.0 for Q2 2026 at NextPlat, up from -$1.1 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $3.4 million in Q3 2023 and troughed at -$6.4 million in Q4 2025.
  • A 5-year average of -$2.2 million and a median of -$1.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders soared 160.35% in 2023 and sank 222.27% in 2024, its largest moves.
  • Over 5 years, Net Income towards Common Stockholders stood at -$941780.0 in 2022, then plunged by 80.3% to -$1.7 million in 2023, then tumbled by 42.4% to -$2.4 million in 2024, then sank by 164.47% to -$6.4 million in 2025, then soared by 97.75% to -$144000.0 in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$144000.0 (Q2 2026), -$1.1 million (Q1 2026), and -$6.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Teva Pharmaceutical Industries 42.34 Bn 38.68 Bn 2.15 Bn -576.00 Mn
2 Viatris 19.39 Bn 18.50 Bn 1.46 Bn -118.80 Mn
3 Dr Reddys Laboratories 9.99 Bn 9.85 Bn 396.53 Mn 46.85 Mn
4 Amneal Pharmaceuticals 5.57 Bn 5.53 Bn 334.51 Mn 69.61 Mn
5 Bausch Health Companies 2.45 Bn 1.58 Bn 2.10 Bn 260.00 Mn
6 Ani Pharmaceuticals 1.70 Bn 1.34 Bn 165.89 Mn 24.70 Mn
7 Alvotech 1.66 Bn 1.52 Bn 2.56 Mn -66.70 Mn
8 Amphastar Pharmaceuticals 985.90 Mn 695.77 Mn 93.47 Mn 30.35 Mn
9 Fennec Pharmaceuticals 434.07 Mn 392.82 Mn 17.15 Mn 1.97 Mn
10 NextPlat 24.77 Mn 12.93 Mn 4.69 Mn -144,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -144,000.00
Mar 31, 2026 -1.12 Mn
Dec 31, 2025 -6.40 Mn
Sep 30, 2025 -2.19 Mn
Jun 30, 2025 -1.79 Mn
Mar 31, 2025 -1.94 Mn
Dec 31, 2024 -2.42 Mn
Sep 30, 2024 -4.22 Mn
Jun 30, 2024 -5.31 Mn
Mar 31, 2024 -1.48 Mn
Dec 31, 2023 -1.70 Mn
Sep 30, 2023 3.45 Mn
Jun 30, 2023 -4.34 Mn
Mar 31, 2023 -1.19 Mn
Dec 31, 2022 -941,780.00
Sep 30, 2022 -5.71 Mn
Jun 30, 2022 -1.66 Mn
Mar 31, 2022 -850,083.00
Dec 31, 2021 -3.54 Mn
Sep 30, 2021 -2.31 Mn